Send PM
Followers 28
Posts 1014
Boards Moderated 0
Alias Born 03/10/2014

FREE
DCTH REPORT

Re: None

Friday, 02/02/2018 9:08:24 AM

Friday, February 02, 2018 9:08:24 AM

Post# of 50118
Delcath Announces 500th Commercial CHEMOSAT Treatment in Europe

NEW YORK, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that physicians in Europe have performed the 500th PHP Therapy® treatment using the company’s Hepatic CHEMOSAT® Delivery System (CHEMOSAT). CHEMOSAT was launched in select European markets in 2012, and physicians there have used it to treat a wide variety of cancers of the liver.

Jennifer K. Simpson, Ph.D., President and CEO of Delcath Systems, said, “this is a meaningful milestone for Delcath, one that speaks to the belief physicians in Europe have developed in our product and this therapy for certain types of liver cancers. Our commercialization efforts in Europe have established a considerable body of published and presented research data that demonstrates the safety and efficacy of this therapy in appropriate patients. Further, Dutch Health Authorities recently included CHEMOSAT treatment in their published guidelines for ocular melanoma liver metastases, a step toward potential reimbursement coverage of CHEMOSAT in the Dutch market. We continue to leverage this experience to validate the safety and efficacy of the melphalan/Hepatic Delivery System (CHEMOSAT) in our clinical trials.”

Percutaneous Hepatic Perfusion (PHP) Therapy with Melphalan/HDS was developed by Delcath Systems as a targeted, whole organ therapy for the liver. It is commercially available as a device in Europe, where it is marketed as CHEMOSAT®. The system has not been approved by the U.S. Food and Drug Administration, and is undergoing Phase 3 clinical testing in the U.S. as an investigational product.

In My Own Personal Opinion Of Course!


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DCTH News